Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

TTPH - Tetraphase Pharmaceuticals Inc.

Previous close
2.2
0   0%

Share volume: 0
Last Updated: Tue 28 Jul 2020 06:00:00 AM CEST
Pharmaceuticals: Other: 0%

PREVIOUS CLOSE
CHG
CHG%
$2.20
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
12%
Profitability 0%
Dept financing 9%
Liquidity 52%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$2.20
P/E Ratio 
N/A
DAY RANGE
$2.20 - $2.20
EPS 
-$18.50
52 WEEK RANGE
$0.56 - $8.60
52 WEEK CHANGE
-$67.07
MARKET CAP 
15.979 M
YIELD 
N/A
SHARES OUTSTANDING 
7.263 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$5,417,970
AVERAGE 10 VOLUME 
$191,479
AVERAGE 30 VOLUME 
$250,875
Company detail
CEO: Larry Edwards
Region: US
Website: http://www.tphase.com
Employees: 67
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceuticals: Other
Sector: Health Technology

Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also engages in the development of product candidate, eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.

Recent news